Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L SlingluffKarl D LewisRobert AndtbackaJohn HyngstromMohammed MilhemSvetomir N MarkovicTawnya BowlesOmid HamidLeonel Hernandez-AyaJoel ClaveauSekwon JangPrejesh PhilipsShernan G HoltanMontaser F ShaheenBrendan D CurtiWilliam SchmidtMarcus O ButlerJuan ParamoJose LutzkyArvinda PadmanabhanSajeve ThomasDaniel MiltonAndrew PecoraTakami SatoEddy HsuehSuprith BadarinathJohn KeechSujith KalmadiPallavi KumarRobert WeberEdward LevineAdam BergerAnna BarJ Thaddeus BeckJeffrey B TraversCatalin MihalcioiuBrian GastmanPeter BeitschSuthee RapisuwonJohn GlaspyEdward C McCarronVinay GuptaDeepti BehlBrent BlumensteinJoanna J PeterkinPublished in: Journal for immunotherapy of cancer (2022)
NCT01546571.